AI Drug Delivery Startup Metis Tech Signs With Eli Lilly in a Deal Worth Up to 1.1 Billion Dollars

Metis Tech, the AI-driven drug delivery company listed in Hong Kong as 7666.HK, announced on October 19 a strategic collaboration with Eli Lilly focused on discovering next-generation lipid nanoparticle delivery technology. The economics are staged in the usual biotech pattern: an upfront payment of more than 10 million dollars to Metis, eligibility for up to 1.1 billion dollars in development, regulatory and commercial milestones, and tiered royalties in the single digits on annual net sales of any collaboration products.

The technology being licensed is AiLNP, an AI nanoparticle delivery design platform that runs on Metis' NanoForge system. Lipid nanoparticles are the delivery vehicles that made mRNA vaccines possible, but finding the right lipid structure for a given tissue has traditionally been an empirical grind - chemists designing candidates by intuition and screening them in bulk. Metis applies generative and predictive AI to design ionizable lipids rationally: its PhatGPT lipid generation model proposes novel structures, and the company says it maintains one of the largest lipid libraries in the industry, spanning more than 10 million distinct chemical structures.

The specific goal is tissue specificity. Today's approved LNPs deliver overwhelmingly to the liver, because the liver hoovers up lipid particles from the bloodstream. Getting payloads reliably into muscle, lung, immune cells or the nervous system is the open problem that would unlock a much wider range of genetic medicines. Metis says its platform has demonstrated delivery targeting to eight key organs and tissues, a claim that matters enormously if it holds up in Lilly's hands and matters little until it does.

Both sides reached for superlatives in the announcement. Chinese financial press, citing public transaction records, described it as the first strategic collaboration in China driven by a generative AI platform around LNP delivery, and the largest AI-driven extrahepatic LNP platform deal globally by disclosed value. Those characterizations come from the company and market coverage rather than an independent ranking, but the headline number is verifiable: no larger AI-LNP platform deal has been publicly disclosed.

Metis has an unusual origin story for a Hong Kong-listed biotech. It was founded in 2020 by Chen Hongmin, a member of the US National Academy of Engineering, together with MIT-trained scientists Lai Caida and Wang Wenshou, and it went public on the Hong Kong Exchange on May 13, 2026, marketed as the first AI drug delivery stock. Beyond AiLNP, the NanoForge platform hosts AiRNA for mRNA sequence design, AiProtein for protein design and AiTEM for small-molecule formulation.

For Lilly, the deal extends an aggressive AI shopping spree. The pharma giant partnered with Nvidia in late 2025 to build what it called the most powerful supercomputer owned and operated by a drug company, then committed in January to a five-year, one-billion-dollar joint research lab in the San Francisco Bay Area. Through 2026 it has signed AI-focused deals with Insilico Medicine, Chai Discovery and Profluent, and more than twenty collaborations with Chinese biotech firms this year alone, according to Securities Times.

The deal is a marker for where AI drug discovery money is flowing: not just into designing molecules, but into the delivery problem that decides whether those molecules ever work in patients. The 1.1 billion dollar figure is milestones, not cash - most such pipelines never collect the full amount. But an upfront above ten million dollars for a platform collaboration, from a partner with Lilly's diligence record, is a concrete vote that generative chemistry has something real to say about the hardest problem in drug delivery.